TY - JOUR
AU1 - Kuntz, Richard E.
AB - Interventional Cardiology Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine- Encapsulated Stent for Treatment of Native Coronary Artery Lesions Clinical and Angiographic Results of the ENDEAVOR II Trial Jean Fajadet, MD; William Wijns, MD, PhD; Gert-Jan Laarman, MD; Karl-Heinz Kuck, MD; John Ormiston, MD; Thomas Münzel, MD, PhD; Jeffrey J. Popma, MD; Peter J. Fitzgerald, MD; Raoul Bonan, MD; Richard E. Kuntz, MD, MSc; for the ENDEAVOR II Investigators Background—The use of the Endeavor stent might reduce restenosis and stent thrombosis at 9 months. Methods and Results—Patients (n
1197) treated for single coronary artery stenosis were enrolled in a prospective, randomized, double-blind study and randomly assigned to receive the Endeavor zotarolimus-eluting phosphorylcholine polymer–coated stent (n
598) or the same bare metal stent but without the drug or the polymer coating (n
599). The 2 groups were well matched in baseline characteristics. Diabetes was present in 20.1% of patients; the mean reference vessel diameter was 2.75 mm; and the mean lesion length was 14.2 mm. The primary end point of target vessel failure at 9 months was reduced from 15.1% with the bare metal stent to 7.9% with the Endeavor (P
0.0001), and the rate of major adverse cardiac events was reduced from 
TI - Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions Clinical and Angiographic Results of the ENDEAVOR II Trial
JF - Circulation
DO - 10.1161/CIRCULATIONAHA.105.591206
DA - 2006-08-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/randomized-double-blind-multicenter-study-of-the-endeavor-zotarolimus-kmxH02HxBM
SP - 798
EP - 806
VL - 114
IS - 8
DP - DeepDyve
ER -